FDA Grants Fast Track to Palisade Bio’s Drug Candidate
The FDA has granted Fast Track designation to Palisade Bio’s investigational drug LB1148 to accelerate the return of bowel function following gastrointestinal surgery.
The protease inhibitor neutralizes digestive enzymes and has the potential to both reduce abdominal adhesions — bands of tissue that could stick to organs — and accelerate the return of bowel function.
The Fast Track process is designed to expedite the review of drugs to treat serious conditions and fill an unmet need. The designation makes drug candidates eligible for more frequent interactions with the FDA.
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
November 28, 2022
